Foldax Named Among Fierce Medtech’s “Fierce 15” Companies of 2020

SALT LAKE CITY--(BUSINESS WIRE)-- Foldax®, Inc. today announced that it has been named by Fierce Medtech as one of the 2020 “Fierce 15,” designating it as one of the most promising private companies in the medical technology industry.

Foldax is reinventing every aspect of the heart valve, from material to design to manufacturing. Its mission is to develop surgical and transcatheter heart valves designed to last a lifetime that address historical tradeoffs, such as durability, disease risk, complications, manufacturing challenges and patient quality of life infringements.

The company’s Tria valve portfolio incorporates a new, proprietary biopolymer – LifePolymer™ – with innovative valve designs intended to resist calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. The Tria valves are the first biopolymer heart valves ever approved by the FDA for human study. Tria is also the first and only artificial heart valve to be robotically produced, which is intended to improve precision, repeatability and quality, and create a more efficient heart valve manufacturing process.

“Each member of this year’s class of ‘Fierce 15’ stands out in a different way, but they all overcame a year of unforgettable obstacles, making each of their successes that much more significant — and all have the potential to deliver changes in healthcare that promise to outlast this pandemic,” said Conor Hale, associate editor of Fierce Medtech.

Each year Fierce Medtech evaluates hundreds of private companies from around the world for its annual “Fierce 15” list. The full list of 2020 “Fierce 15” winners can be viewed here.

About Foldax

Headquartered in Salt Lake City, Utah, Foldax is reinventing every aspect of the heart valve – from material to design to manufacturing – to develop surgical and transcatheter valves designed to last a lifetime addressing historical tradeoffs. Foldax investors include Angel Physicians Fund, Biostar Capital, Caltech, Kairos Ventures, Memorial Care Innovation Fund and Sayan Bioventures.

About Fierce Medtech

Fierce Medtech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology. More than 90,000 top industry professionals rely on Fierce Medtech for an insider briefing on the day's top stories.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005145/en/

Michelle McAdam, Chronic Communications, Inc.
[email protected]
(310) 902-1274

Source: Foldax

You May Also Be Interested In

• IMCD reports EBITA of EUR 127 million in the first three months of 2024
• Signify reports first quarter sales of EUR 1.5 billion, operational profitability of 8.3% and a free cash flow of EUR 80 million
• Corbion: Q1 2024 Interim Management Statement